MT-103

N/A

Report date: 2026/05/11 20:01:57

Base Information

Drug NameMT-103

Drug Alias NameMT-103

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Macrophages therapy > Chimeric antigen receptor Macrophages therapy > in vivo CAR-Macrophages therapyCell and gene therapy > Cell therapy > In vivo cell therapy > in vivo CAR-Macrophages therapyCell and gene therapy > Gene therapy > mRNA

Mechanisms of ActionAnti-Trop-2

TargetsTumor-associated calcium signal transducer 2

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesMyeloid Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A